Effects of vinorelbine and titanocene dichloride on human tumour xenografts in nude mice

European Journal of Gynaecological Oncology

Volumn 19, Issue 4, 1998, Pages 333-337

  Friedrich, M ^a,b   Villena Heinsen, C ^a   Farnhammer, C ^a   Schmidt, W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Cisplatin; Nude mice; Paclitaxel; Titanocene dichloride; Tumour growth; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; NAVELBINE; PACLITAXEL; TITANOCENE DICHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CISPLATIN; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE;

EID: 0031824144     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hunter R. W., Alexander N. D., Soutter W. P.: "Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery and independent determinant of prognosis?". Amer. J. Obstet. Gynec., 1992, 166, 504.
2. Thigpen J. T.: "Chemotherapy in the management of celomic epithelial carcinoma of the ovary". In: Cancer of the Ovary. Markman M-., Hoskins W. J. eds., New York, Raven Press, 1993, 277.
3. Williams C. J , Stewart L , Pharmar M., Guthrie D.: "Metaanalysis of the role of platinum compounds in advanced ovarian carcinoma". The Advanced Ovarian Cancer Trialists Group. Semin. Oncol., 1992, 19, 120.
4. Edmonson J. H., Su J., Krook J. E.: "Treatment of ovarian cancer in elderly woman". Mayo Clinic - North Central Cancer Treatment group studies". Cancer, 1983, 71, 261.
5. Gershenson D. M., Mitchell M F., Atkinson N.: "Age contrast in patients with advanced epithelial ovarian cancer: the M. D. Anderson Cancer Center experience". Cancer, 1993, 71, 638.
6. Thigpen J. T., Bertelsen K., Eisenhauer E. A. Hacker N. F., Lund B., Sessa C.: "Longterm follow-up of patients with advanced ovarian carcinoma treated with chemotherapy". Ann. Oncol., 1993, 4, 35.
7. Pfleiderer A.: "Tumor reduction and chemotherapy in ovarian cancer". Bailliere's. Clin. Obstet. Gynec., 1989, 3, 119.
8. McGuire W. P., Hoskins W. J., Brady M. F., Homesley H. D., Clarke-Pearson D. L.: "A phase III trial of dose-intense (DI) vs. standard-dose (DS) cisplatin (CDDP) and cytoxan (CTX) in advanced ovarian cancer (AOC) (meeting abstract)". Proc. Annu. Meet. Amer. Soc. Clin. Oncol., 1995, 11, A718.
9. Frasci G., Comella G.: "Carboplatin-hexamethylmelamineoral etoposide first-line treatment of ovarian cancer patients with bulky disease: a phase II study". Gynec. Oncol., 1995, 58, 68.
10. Roussakis C., Pouchus Y. F., Gratas C.: "In vivo study of vinorelbine associations with cisplatin, 5-fluorouracil or actinomycin D relative to a non-small-cell lung carcinoma (NSCLCN6-L16)". Anticancer Drug Res., 1993, 8, 165.
11. Etièvant C., Kruczynski A., Pauwels O.: "The combination of the tetrazolium derivative reduction (MTT) and digital cell image analysis to monitor in vitro the cytotoxicity of antineoplastic drugs". Anticancer Res., 1991, 11, 305
12. Kobayashi S., Sakai T., Dalrymple P. D.: "Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs". Arzneimittel-Forschung, 1993, 43, 1367.
13. Van Tellingen O., Kuijpers A., Beijnen J. H.: "Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography". Invest. New Drugs, 1993, 11, 141.
14. Bore P., Rahmani R., van Cantfort J.: "Pharmacokinetics of a new anticancer drug, navelbine, in patients". Cancer Chemother. Pharmacol., 1989, 23, 247.
15. Zhou X. J., Rahmani R.: "Preclinical and clinical pharmacology of vincaalkaloids". Drugs, 44 Suppl., 1992, 4, 1.
16. Romero A., Rabinovich M. G., Vallejo C. T.: "Vinorelbine as first-line chemotherapy for metastatic breast carcinoma". J. Clin. Oncol., 1994, 12, 336.
17. Moebius V. J., Stein R., Kieback D. G., Runnebaum I. B., Sass G., Kreienberg R.: "Antitumour activity of new organometallic compounds in human ovarian cancer cell lines and comparison to platin derivates". Anticancer Research, 1997, 17, 815.
18. Köpf-Maier P.: "Tumour inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract. Cancer Chemother. Pharmacol., 1989, 25, 225.
19. Kurbacher C. M., Nagel W., Mallmann P. et al: "In vitro activity of titanocenedichloride in human renal cell carcinoma compared to conventional antineoplastic agents". Anticancer Research., 1994, 14, 1529.
20. Harstrick A., Schmoll H. J., Sass G., Poliwoda H., Rustum Y.: "Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines". Eur. J. Cancer, 1993, 29(7), 1000
21. Köpf-Maier P.: "Complexes of metals other than platinum as antitumour agents". Eur. J. Clin. Pharmacol., 1994, 47, 1.
22. Kurbacher C. M., Bruckner H. W , Andreotti P. E., Kurbacher J A., Sass G., Krebs D.: "In vitro activity of titanocenedichloride versus cisplatin in four ovarian cell lines evaluated by microtiter plate bioluminescence assay". Anti-Cancer Drugs, 1995, 6, 697.
23. Cao S., Durrani F. A., Baumgart J., Sass G., Rustum Y.: "Titanocene dichloride a new organometallic compound, active in vivo against varieties of human tumours with differential sensitivity to doxorubicin and cisplatin". Proceedings of the 86th Annual Meeting of the American Association for Cancer Research, March 18-22, 1995, Toronto, Ontario, Canada; Volume 36, 391.
24. Köpf-Maier P.: "Intracellular localization of titanium within xenografted sensitive human tumours after treatment with the antitumour agent titanocene dichloride". J. Struct. Biol. (J. Ultrastruct. Mol. Struct. Res.). 1990, 105, 35.
25. Christodoulou C., Ferry D., Fyfe D et al.: "Phase I clinical trial of titanocene dichloride (TD) with pharmacokinetic analysis". Proceedings of the 88th Annual Meeting of the American Association for Cancer Research, April 12-16, 1997; San Diego, CA; Volume 38, 1495.
26. Berdel W. E., Schmoll H. J., Scheulen M. E., Korfel A , Gründel O., Harstrick A.: "Phase I clinical and pharmacokinetic study of titanocene dichloride in advanced solid tumours". Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology, May 20-23, 1995; Los Angeles, CA; Volume 14, 1512.
27. Azar H. A., Fernandez S. B., Bros L. M., Sullivan J. L.: "Human tumour xenografts in athymic nude mice: chemotherapy trials in serially transplanted tumours". Ann. Clin. Lab. Sci., 1982, 12, 51.
28. Kyriazis A. A., Kyriazis A. P., Kereiakes J. G., Soloway M. S., McCombs, W B.: "Histopathologic evaluation of response to treatment of human tumours grown in the nude mice". Exp. Cell. Biol., 1983, 51, 83.
29. Shorthouse A. J., Smyth J. F., Steel G. G., Ellison M., Mills J., Pecham M. J.: "The human tumour xenograft a valid model in experimental chemotherapy". Brit. J. Surg., 1980. 67, 715.
30. Steel G. G., Courtenay V. D., Peckham M. J.: "The response to chemotherapy of a variety of human tumour xenografts". Cancer, 1983, 47, 1.
31. Köpf-Maier P., Köpf H.: "Metallocene complexes: Organometallic antitumour agents". Drugs of the Future, 1986, 11(4), 297.
32. Venditti J. M.: "Preclinical drug development: rationale and methods". Sem. Oncol., 1981, 8, 349.
33. Goldstein R. S., Mayor G. H.: "Mini-review: the nephrotoxicity of cisplatin". Lifi. Sci., 1983, 32, 685.
34. Cvitkovic E., Izzo J.: "The current and future place of vinorelbine in cancer therapy". Drugs, 1992, 44 Suppl., 36.
35. Weber B., Vogel C., Jones S.: "A US multicenter phase II trial of Navelbine in advanced breast cancer (abstract no. 46)". Proceedings of ASCO, 1993, 12, 61.
36. Coppola F., Balbiani L., Blajman C.: "Vinorelbine (VNB) containing regimens in three different schedules for the treatment of advanced breast cancer (ABC) (abstract no. 144)". Proceedings of ASCO, 1994, 12, 108.
37. Ferrero J. M., Wendung J. L., Hoch M.: "Mitoxantrone (MTZ)-vinorelbine (VNR) as first line chemotherapy (CT) in metastatic breast cancer (MBC): a pilot study (abstract no. 234)". Proceedings of ASCO, 1993, 12, 108.
38. Scheithauer W., Kornek G., Haider K.: "Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C". Breast Cancer Res. Treat., 1993, 26, 49.
39. Héron J. F., George M. J., Kerbrat P.: "Phase II study of Navelbine as second or third line treatment in advanced ovarian carcinoma". In: Solal Celigny P., ed. Navelbine (vtnorelbine): Update and New Trends. Montrouge, John Libbey Eurotext Limited, 1991. 231.
40. Pinel M. C., Pinon G., Goudier M. J.: "Study of the combination vinorelbine-hexamethyl-melamine (V-H) in advanced ovarian adenocarcinoma: preliminary results of a phase I-II study NHO-88. from the ARTAC multicentric ovarian carcinoma study group"" In: Solal Celigny P., ed. Navelbine (vinorelbine): Update and New Trends. Montrouge, John Libbey Eurotext Limited. 1991, 237.
41. Burger R. A., DiSaia P. J., Boyle J.: "Phase II trial of Navelbine in the treatment of women with advanced epithelial ovarian cancer (abstract no. 15)". Gynecal. Oncol., 1993, 50, 268.